ghpBiotechnology & Lifesciences Awards 2025 Biotechnology & Lifesciences Awards 2025 www.ghp-news.com Featuring:
Global Health & Pharma Magazine is proud to announce the launch of the Biotechnology & Lifesciences Awards. Biotechnology & Lifesciences Awards 2025 Previously two separate entities (The Biotechnology Awards and the International Lifesciences Awards) the 2025 edition will showcase the pioneering companies in the Biotech and Lifesciences sectors. With a combined 17 years of experience, the Biotechnology & Lifesciences Awards 2025 will once again be dedicated to honouring the visionary companies and innovators at the forefront of the Scientific Industry. The Biotechnology and Lifesciences Sectors stand as a pillar of modern innovation, driving breakthroughs that are not only reshaping industries but also redefining the possibilities for human health, sustainability, and beyond. Among the leading sectors within Biotechnology and Lifesciences field, Healthcare remains at the forefront, with companies developing cuttingedge therapies, personalised medicine, and gene-editing technologies that are poised to cure previously untreatable diseases. The promise of these innovations extends beyond human health, with applications in animal health and agriculture that could transform global food security. Sofi Parry, Senior Editor Website: ghpnews.digital AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.
Contents 4. Almaral VC: Best Early-Stage BioTech Investment Start-Up 2025 – Europe 6. Brain Health Formulas Biotechnologies: Best Natural BioTech Company 2025 – USA 8. Antharis Therapeutics: Most Pioneering Biopharmaceutical Therapeutics Company of 2025 – USA & GHP Innovation Excellence Award of Year 2025 9. BioLogic Pharma Solutions: Best Emerging BioTech & Pharmaceutical Consulting Firm 2025 – USA & GHP Client Service Excellence Award 2025 10. VasoDynamics Ltd: Cancer Care Solutions Provider of the Year 2025 – UK 11. Trestle Compliance, LLC: Best Life Science Commercial Business Compliance Specialists 2025 – North America & GHP Innovation Excellence Award 2025 12. Connect 2 Cleanrooms: Cleanroom Design & Installation Company of the Year 2025 13. Altasciences: Best Biopharmaceutical CRO 2025 14. Mestastop Solutions Pvt Ltd: Best Metastasis R&D Specialist 2025 & GHP Innovation Excellence Award 2025 15. biomindz: Life Science Hub of the Year 2025 – Europe & GHP Innovation Excellence Award 2025
4 Regardless of intention, successfully breaking into the biotechnology and life sciences industry can be an incredibly daunting task. Navigating the labyrinth of strict regulations, funding obstacles, and scientific validation seems like an impossible journey for many emerging entities and often leaves them doubting that their product will ever reach the market. Enter Almaral – a leading venture capital firm that specialises in funding and advising early-stage companies in the biotechnology and life sciences sector. We heard more from CEO and Founder Dr Maria Severina below, as the company is named in the Biotechnology and Life Sciences Awards 2025. Dr Maria Severina founded Almaral after the successful sale of her biotechnology company HyTest, which she had owned and operated as its CEO since 1994. Following her extensive time leading HyTest to success, she was perfectly positioned to leverage her wealth of knowledge to help others. In 2022, Dr Severina co-founded Almaral with her husband Alex Michine to share this expertise, forming a family-owned venture capital firm dedicated to investing in earlystage biotechnology and life sciences start-ups. A special advisory and investment firm focused on life sciences, biotechnology, digital health, and medtech, Almaral works closely with innovative start-ups, growth-stage companies, and investors, providing strategic guidance and support to accelerate business growth. Alongside Dr Severina’s vast industry knowledge, the firm leverages a combination of in-depth market analysis and a strong network of experts to identify and support the most promising innovations in the field. It is this combination that gives Almaral its distinct competitive edge; the company’s industry expertise, hands-on advisory approach, and extensive network within the life sciences and biotech sector position it as a frontrunning firm in the industry. “We are more than just investors – we are active partners,” stated Dr Severina, “guiding companies through complex markets and helping them scale successfully. In fact, Almaral has been recently recognised for its excellence by Life Science Review, named the Life Sciences Consulting Company of the Year in Europe 2024. This award is a notable achievement and a direct demonstration of Almaral’s domination of the biotechnology and life sciences sector, underlining the firm’s commitment to delivering nothing short but excellence across its operations. Almaral aims to leverage this success to propel itself forward in the market, continuing to revolutionise the industry through innovation and expertise. Working above and beyond the scope of a traditional venture capital company, Almaral not only offers investments and funding but also business and marketing consulting and legal services to innovative and growth-oriented companies in the industry. The firm creates value for its clients by addressing the strategic and operational enquiries and challenges that a start-up company may face in its initial stages. With a distinct lack of angel investor capital in the industry, Almaral serves its clients as the one-stop-shop for growth minded companies by offering unparalleled funding, legal, and marketing consulting services alongside a network of partners to provide operational support. This comprehensive service offering is rare in the complex world of biotechnology and life sciences and provides invaluable support to countless companies and start-ups emerging throughout the sector. Of course, Almaral has an exceptional industry reputation, earned partly due to its meticulous investment criteria. To qualify for Best Early-Stage BioTech Investment Start-Up 2025 – Europe
GHP Biotechnology & Lifesciences Awards 2025 Almaral’s outstanding offerings, applicants must have a biotech and life sciences start-up within Europe; their investment needs must range from €0.5 million to €1 million; their company must possess a capable team with the necessary skills to implement its business plan; its valuation must be in line with its development stage; a board position is anticipated in the agreement; a liquidation preference clause must be included in the agreement; and the company must follow ESG principles in alignment with Almaral’s own commitments. To maintain its excellent reputation, Almaral also understands the importance of regulatory compliance. “While Almaral itself is not directly regulated, each of our portfolio companies adheres to the relevant industry standards – whether for medical devices, pharmaceuticals, or digital health data,” Dr Severina told us. “Our role is to ensure that these companies comply with all necessary regulations and best practices. We also stay at the forefront of industry developments by maintaining close relationships with regulatory bodies, industry experts, and key stakeholders.” Almaral’s partnership approach is not only applied externally, but also internally; the company fosters a culture of collaboration, innovation, and integrity. The company prioritises long-term relationships, knowledge-sharing, and a proactive approach to problem-solving. This culture translates into the ways in which Almaral supports its portfolio companies, ensuring that they have ongoing access to the resources, tools, and guidance they need to thrive in a complex landscape. This is ensured through Almaral’s stringent hiring process, which has been carefully developed to attract and retain the most capable and suitable industry talent. The firm seeks individuals who are passionate about life sciences innovation and possess strong industry expertise. Its hiring process focuses on professionals who not only display technical skills but also bring strategic insight and a collaborative mindset. “We attract top talent by offering opportunities to work on cutting-edge projects and fostering an environment of continuous learning and professional growth,” Dr Severina added. Opportunities for growth are rife in the biotechnology and life sciences industry, which is characterised by its continual demand for ongoing development and advancement. At present, Almaral observes that the sector is currently navigating significant challenges, comprising economic uncertainty, regulatory changes, and shifting investment trends. Despite these hurdles, however, the demand for inimitable innovation in life sciences, biotech, digital health, and medtech remains as strong as ever. As healthcare and technology continue to evolve, driving one another’s advancement, the unparalleled expertise possessed by Almaral remains in exceptionally high demand. This promises an especially prosperous future for Almaral, a company with big plans for expansion and enhancement in the upcoming year. “In 2025, we plan to expand our investment portfolio, strengthen partnerships with key players in the life sciences industry, and support the international scaling of high-potential start-ups,” said Dr Severina. “We are particularly focused on emerging biotech and digital health technologies that have the potential to revolutionise patient care and medical innovation.” Since its inception, Almaral has been dedicated to empowering emerging companies and start-ups within the biotechnology and life sciences industry, providing them with invaluable expertise and guidance as they embark on their arduous adventure. With Almaral’s expert support, its portfolio companies have made significant strides in their respective fields, and the company remains committed to supporting their growth and expansion. Almaral has distinguished itself in the market through its unique service model – showcasing unparalleled expertise, providing specialist support, and making a significant contribution towards the advancement of Europe’s biotechnology and life sciences sector. These achievements have established Almaral as an industry frontrunner and has earned the firm the prestigious title of Best Early-Stage BioTech Investment Start-Up 2025 – Europe. Contact: Dr Maria Severina Company: Almaral VC Web Address: www.almaral.eu
6 AIS-Feb25024 Based on traditional Chinese medicine, ancient Indian medicine such as Ayuveda, and thousands of years of indigenous tribal remedies, as well as scientific research and discoveries, Brain Health Formulas Biotechnologies is an outstanding natural BioTech company combining the healing herbs of our past with unique proprietary amino acid complex of the present time. We caught up with Owner Derek Lee as the company was recently awarded in our Biotechnology&LifesciencesAwards2025. n January of 2019, prior to his creation of Brain Health Formulas Biotechnologies, Derek Lee was diagnosed with more than 13 autoimmune disorders/diseases in a 4-year timeframe, starting in 2016-2020Including MS to Cerebral Palsy in addition to Parkinson’s disease, dementia, and ALS, Derek was almost convinced that his conditions would never be reversed. He knew deep down that there was hope, and this was when the idea for Brain Health Formulas Biotechnologies was born. He told us: “I started working on a way to repair my brain around April of 2019 as I truly recognized my brain was failing. Western medicine has no answers on how to repair the brain, so I decided to take a step back and view humans at their most basic form (chains of amino acids).” Through his ongoing process of being diagnosed with polycythemia among many other disorders or diseases leading up to the tumultuous time of the global pandemic, Derek was donating blood every 1-2 weeks to reduce the pressure in his head – with a prescription to do so. He found that his inspiration for the early stage development for his amino acid complex came to life in in October 2019, before the pandemic struck. Along with the kickstart of his products, March 2020 saw the final time Derek needed to give blood – after just a month using his amino acid complex for regeneration. His primary product, Restore, helped Derek to heal his autoimmune diseases/disorders which became non-detect within 6 months. He enthused: “An additional 6 months and the majority of my memories had been reconnected or became accessible again. I spent the next 2 years analyzing how my product works. I also gave away hundreds of bottles of Restore during Covid, believing Restore could combat Covid by activating the brain and by default activates our immune system. We found out our assumption was correct.” “Our specific nature of business has to do with redefining the science of health and being able to communicate what health is.” Brain Health Formulas Biotechnologies’ monumental range of offerings include: The Restore Range From memory capsules to capsules for autoimmune disorders, Parkinson’s relief capsules to candida overgrowth and Restore for MS, general health and well-being to Restore for Diabetes and ALZ capsules, the Restore Range has something for most conditions/ autoimmune diseases/disorders. Inter-Cell The Inter-Cell capsules are dedicated to the rehydration of the cellular matrix, ultimately helping to improve the health and functionality of any person – no matter their age or conditions. Brain Health Formulas Biotechnologies is a firm believer that its meticulous design process is able to improve the fluid balance with our cellular matrix to ensure our organs, glands, and bones are optimized within the collagen-based environment. Dragon’s Blood Capsules Using dragon’s blood, a tree resin, to deliver anti-inflammatory results, Brain Health Formulas Biotechnologies continues to improve the health of its customers through natural products known throughout ancient medicinal practices. As dragon’s blood has been used for the highest record numbers – on the ORAC rate of measure – of anti-oxidants, this devoted company is delivering this sacred ingredient’s benefits for the healing of intestinal tract, inflammation, stomach ailments, lungs, kidney, liver, and heart issues. The examples above are only some of the products on offer from Brain Health Formulas Biotechnologies’ expertise and passionate approach to natural health products creating harmony between our thousands of years in traditional, holistic medicine, and science as we know it today. Furthermore, Derek said: “Everything we do is in small batches. We follow standard GMP protocols. We can formulate a product for an individual who has specific needs. We can build custom formulas for just about any issue that is known. We have formulas to target fungus, yeast, and mold. We have formulas to activate enzyme production in the brain. With these formulas we can isolate a problem and then formulate or combine products to benefit an individual’s issue.” With regards to the future, especially as this year unfold before us, Derek added: “One of the components we are working on in 2025 is to analyze the specifics of each neurodegenerative disease and build a formula for each one. We currently have a broad version which will take about a year to address the issues now. We believe if we can target each one we can speed up the process and we are using natural ingredients, worst case scenario is zero results. “We can also adapt a formula to cater to each individuals needs because we have built every formula from scratch and we know what each ingredient does and the implication it has on an individual, yes, we can custom build a formula to meet everyone’s needs because we are all different!” With its pioneering products and ‘think outside the box’ attitude pushing the company forward, Brain Health Formulas Biotechnologies has truly built a reputation for excellence, dedication, and a fresh outlook on the world of medicine. With this, Derek commented: “Individuals need to have a big picture or at least know there is a much bigger picture available.” If you wish to learn even more about how this company’s innovative products can help you or those you know, contact Derek and Brain Health Formulas Biotechnologies today. Best Natural BioTech Company 2025 – USA I
GHP Biotechnology & Lifesciences Awards 2025 Email: derek@brainhealthformulas.com Contact: Derek Lee Company: Brain Health Formulas Biotechnologies Website: http://brainhealthformulas.com/
8 GHP Biotechnology & Lifesciences Awards 2025 Based in San Diego, California, Antharis Therapeutics is a company committed to addressing unmet medical needs of patients worldwide, particularly in oncology, through the power of biotherapeutics. With a focus on precision medicine and an extensive portfolio of targetedoncologyandimmuno-oncology innovations, Antharis has proven itself more than adept when it comes to leveraging cutting-edge technologies that accelerate the development of lifesaving treatments. Antharis was founded on the belief that revolutionary research and scientific breakthroughs should lead to demonstrable medical advancements that transform lives. Founded by visionary entrepreneur Dr. Raphael R. Pinaud, who serves as the company’s CEO & Chairman, Antharis is built on a foundation of innovation, expertise, and a commitment to reshaping cancer treatment. At the core of the company is a multidisciplinary team of experts in fields such as molecular and cellular biology, immunology, chemistry and translational medicine, all of whom push the very boundaries of therapeutic innovation. The results of their efforts are opening new frontiers in drug development, advancing the potential for life-changing treatments. Antharis collaborates with a select group of partners to serve a diverse client base, ranging from emerging biotechnology companies aiming to establish themselves, to multinational pharmaceutical companies looking to diversify their asset portfolios by investing in innovative new products. Since its inception, Dr. Pinaud has guided Antharis Therapeutics with his wealth of experience across science, finance and business arenas, playing an essential role in the company’s success at every stage. His strategic vision, creativity, and multidisciplinary approach have positioned Antharis as a top emerging biotech company, setting it apart within the industry and driving breakthrough innovations in oncology and immuno-oncology. Committed to advancing cutting-edge science, Dr. Pinaud has assembled a team of exceptional talent - individuals who are not only among the best in the industry but also invested stakeholders in Antharis, giving them a deep sense of responsibility in shaping its success. This has fostered a culture rooted in collaboration, intellectual rigor, and alignment, which has been invaluable in driving high-quality decisions across the company’s cancer treatment programmes. Highlighting recent projects led by Antharis, Dr. Pinaud shares the exciting progress made through the company’s lead immunooncology and antibody-drug conjugate programmes - both of which have shown promising pre-clinical results in targeting treatment-resistant tumors across various cancer types. As Dr. Pinaud explained: “These novel therapeutic approaches have the potential to fundamentally redefine treatment paradigms in oncology.” Supporting this, Antharis’ advanced pipeline is driven by a steady stream of biotherapy solutions specifically designed to target solid tumours. By developing treatments for a wide range of cancers, the company is making significant strides toward a future where the complexities of tumour biology are not only understood but effectively addressed. In the long term, this will lead to the widespread deployment of therapeutic solutions across various cancer types, offering the potential to save countless lives. In addition to its treatments, Antharis is evolving into a clinicalstage company, with plans to advance three of its lead assets into clinical trials this year. This major milestone underscores the company’s commitment to delivering high-impact therapies for conditions with limited treatment options. Dr. Pinaud explained: “These assets have demonstrated exceptional therapeutic potential in pre-clinical studies, and we are excited to move them into the clinic with the ultimate goal of helping patients across various cancer types.” Having secured these launches, Antharis is also focused on expanding and advancing its pipeline, with plans to bring more products into clinical development. Multiple assets are currently in progress, and the company is leveraging biomarkerdriven approaches and AI to streamline efforts, reduce development timelines, and increase success rates. To ensure continued progress, Dr. Pinaud and the team are strengthening collaborations with strategic partners while also investing in internal training and growth. “In summary, we are at a pivotal moment in our journey, and 2025 marks a transformative year as we officially transition to a clinical-stage company,” says Dr. Pinaud in closing. “Antharis is not merely entering the clinic - we are doing so with a robust pipeline of assets positioned for success. Supported by cuttingedge science, a strategic vision, and a world-class team, we are moving forward with the goal of making a real impact for patients and shaping the future of medicine.” We wish Dr. Raphael R. Pinaud and the entire team the best of luck in pursuing their overarching vision, celebrating their impressive success in biotherapeutics so far with these two well-deserved awards. Contact Details Contact: Dr. Raphael R. Pinaud Company: Antharis Therapeutics Web Address: https://www.antharistherapeutics.com/ Most Pioneering Biopharmaceutical Company of 2025 – USA & GHP Innovation Excellence Award of Year 2025 AntharisTherapeutics
9 GHP Biotechnology & Lifesciences Awards 2025 triving to forever revolutionise biotech product launches using fractional medical affairs , BioLogic is transforming the way companies in this space work and empowering them through a flexible, project-based model of engagement . By eradicating the need for expensive and risky full-time equivalent (FTE) methods, the process of launching new projects is made faster, more efficient, and less expensive in the long run with the consulting services offered by the firm resulting in tailored support grounded in expertise . The bespoke approach adopted by BioLogic leads not only to the acceleration of a client’s clinical development, but also aids in enhancing strategy and reshaping of the dynamics in the market around their client companies . As Mary Hames, the firm’s CEO, explains: “BioLogic ensures our clients achieve their goals with efficiency and impact. Combining innovation with deep industry expertise, we strengthen physician relationships and guide clients through the complexities of the biopharma landscape.” As for some examples of the stellar work that the firm has done, a taste of completed projects includes outreach and feasibility efforts for a client approaching Phase 3 of clinical trial with more than 50 institutions registering their interest for a trial involving a rare disease. Moreover, in order to enhance recruitment during these Phase 3 trails, the team have developed and launched an informative and intuitive patient-facing website. Initiatives such as these are simply the tip of the spear, however. One of the most exciting ventures the team have worked on in recent months has been a full evaluation of US commercial diagnostic laboratories involving the identification of gaps in genetic diagnostic capabilities across the clients’ main areas of focus. At time of writing, these findings are just a few days removed from being presented in poster format at a variety of prominent congresses across the country. Despite leading the charge in this sector, it is not always plain sailing for BioLogic, which navigates the challenges that arise from working with companies that are locked in a cycle of continuous change. With the regulatory environment evolving as much as those within it, the degree of difficulty is compounded. Thus, Mary told us: “Part of our value is helping these companies with a scalable, flexible solution during these difficult times.” When it comes to traversing a landscape fraught with pitfalls, BioLogic succeeds by ensuring that its work closely follows EMA and FDA regulations, as well as by attending talks and meetings Headquartered in Grand Haven, Michigan, BioLogic Pharma Solutions is quickly rising up the ranks to become one of the premier fractional medical affairs consulting firms in the pharmaceuticalandbiotechindustries.Withafocusonclinicalstrategy,development,and trial execution, it is the team’s wide range of specialisations – including various medical affairs core capabilities, clinical development , and genetic diagnostics optimisation – that sets them apart and enables superior product launches. We were able to catch up with CEO Dr. Mary Hames to find out more. Best Emerging BioTech & Pharmaceutical Consulting Firm 2025 – USA & GHP Client Service Excellence Award 2025 on the leading edge of industry trends and regulatory shifts. The unique fractional medical affairs support model also plays a big part in the firm’s success, as it sees the team become an extension of the client’s operation, leading to seamless integration and strategic alignment at every turn. When it comes to BioLogic’s internal culture, working in a united fashion towards common goals are prioritized in parallel with individual well-being and growth. Building the ‘Dream Team’ involves recruiting proven talent and providing opportunities for proactive development, values at the very heart of the firm. This unwavering commitment to its team has resulted in BioLogic experiencing significant growth over the past couple of years, with its staff becoming knowledgeable on the current trends defining this market, such as AI, diagnostics, KOL engagement, and more. For Mary: “We believe our strong team and culture are a competitive advantage in our industry, as happy, engaged workers frankly do better work.” Having spent the final quarter of last year honing its scalability processes and developing several innovative technologies in the fields of congress execution and medical information handling, BioLogic Pharma Solutions is excited to be working towards a future of welcoming new customers into the fold and continuing to scale its growth. We wish Mary and the team at this multiaward-winning firm all the best as they work towards these aims. Contact: Mary Hames Company: BioLogic Pharma Solutions Web Address: https://biologicpharmasolutions.com/ S AIS-Mar25010 BioLogicPharmaSolutions
10 GHP Biotechnology & Lifesciences Awards 2025 ased in Stevenage, VasoDynamics is a clinical stage pharmaceutical company dedicated to developing a portfolio of patient-friendly, cost-efficient treatments to prevent the debilitating and distressing complications of cancer therapies. At present, this trailblazing company’s first topical drugs are focused on targeting three common side effects of cancer treatments: an oral topical drug for Oral Mucositis caused by radiotherapy; a scalp topical drug for alopecia caused by chemotherapy; and a dermal topical drug for dermatitis caused by radiotherapy. VasoDynamics was founded in 2020 by Dr. Fiona Ningfeng Li, a trained Radiation Oncologist and Scientist with extensive research experience in tumour biology and carcinogenesis. During her clinical career, Fiona witnessed the debilitating and distressing side effects congruent with cancer treatments, sparking a steadfast and lifelong dedication to improving patient journeys and outcomes from cancer treatments through the prevention of such serious side effects. Behind Fiona is an experienced and diversified team whose innovation and dedication has earned the support from well-established and reputable financial, legal, and corporate governance firms. A young biotech company, VasoDynamics is driven by dynamic, seasoned professionals who share a commitment to the development of safe and effective medicines. To achieve this mission, the company fosters a culture of open discussion and input from both internal and external teams, vendors, and stakeholders. To retain such a high-performing team, Fiona told us that VasoDynamics maintains a strategic approach to its expansion. “Our robust hiring processes ensure that we select and retain team members with the appropriate experience, values, training, and Feb25228 B While lifesaving, cancer treatments can lead to severe and debilitating side effects. From oral mucositis to alopecia to dermatitis, these conditions not only impact physical health but also affect the emotional wellbeing and quality of life for patients, who are already navigating the emotional and physical toll of their diagnosis. Such side effects add layers of discomfort, stress, and frustration to an already difficult journey. VasoDynamics is a pioneering pharmaceutical development company focusing on creating therapies to mitigate these conditions and improve the quality of life for cancer patients. We heard more from Founder and CEO, Dr Fiona Ningfeng Li below. qualifications for their role,” she said. “Our staff receive ongoing support and training in accordance with their roles and experience, to ensure that VasoDynamics is aligned with the ever-evolving clinical research, commercial, and healthcare landscapes.” In such a rapidly advancing landscape, VasoDynamics distinguishes itself with its innovative product offering. Addressing an unmet clinical need, the company provides treatments for three common and severe side effects of cancer therapies for which no approved preventative pharmaceuticals currently exist. Its patient-friendly and cost-effective topical formulations are designed to reduce these side effects, enhancing patients’ quality of life by minimising hospitalisation and ensuring continuity in vital cancer treatments. These groundbreaking benefits position VasoDynamics as a beacon of innovation and ingenuity within the market. VasoDynamics has made significant strides in its clinical programmes. The company successfully completed its NG112 Phase Ib clinical trial in 2024, targeting the reduction and prevention of radiotherapy-induced Oral Mucositis. The clinical story report has been finalised, and the team presented their findings through research posters at the ESTRO Annual Meeting 2024 and MASCC Annual Conference 2024. Demonstrating its commitment to patient engagement and addressing diverse healthcare needs, VasoDynamics also participated in key events, including the Oncology Professional Care conference in London, the Head and Neck Cancer conference in Sheffield, and the Breast Cancer Symposium 2024 in London. Through the NG12-1 programme, focused on reducing severe radiodermatitis in radiotherapy patients, VasoDynamics is exploring managed access, supported by positive results from its Phase Ila trial in the USA. Significant progress has also been achieved in the NG13-2 programme, addressing chemotherapy-induced alopecia, with advancements in formulation optimisation and the futureproofing of its Investigational Medicinal Products supply chain. These clinical trials adhere to stringent global and national regulations, ensuring compliance through VasoDynamics’ robust quality systems and highly qualified teams. As for the future, VasoDynamics understands the need for an emerging, yet pioneering, company to remain adaptable and focused on its mission of directly addressing the unmet needs of patients undergoing cancer treatments. “Drug development poses many challenges, and success is contingent on many factors – some predictable and some not!” Fiona concluded. “Fundraising in the Life Sciences arena remains challenging, and this can be amplified for young biotech companies who must remain nimble, focused, and lean – especially in their early stages. “To realise and develop the full value of our products, VasoDynamics must address current clinical, health economic, and commercial requirements while exploring all channels to tackle underserved and unmet needs in the cancer care landscape.” Contact: Dr. Fiona Ningfeng Li Company: VasoDynamics Ltd Web Address: https://vasodynamics.co.uk/ Cancer Care Solutions Provider of the Year 2025 – UK
11 GHP Biotechnology & Lifesciences Awards 2025 trend, it also offers the same level of support when it comes to assisting life sciences companies as they shift their focus to rare diseases and therapies – another increasingly common pursuit. More often than not, these injectable solutions necessitate both significant patient support as well as a high standard of privacy protocols across the company and the third parties they work with. Again, in this area, it is TRESTLE Compliance that comes to the rescue. Staying up to date with the wealth of developments that occur in the privacy legislation realm is no easy task, especially when it comes to state-level regulations and other developments such as increased federal HIPAA enforcement and decreased accessibility to the offices of health care professionals. Clearly, navigating this industry is very difficult, with the team at TRESTLE Compliance monitoring sector-specific developments at both a national and an international level to afford clients the latest information. Ultimately, by seamlessly combining “the best software with the best ‘thoughtware’,” TRESTLE Compliance is able to deliver a bespoke solution fitting of every client’s unique situation. Its team are unrivalled in what they do and it is their passion that has resulted in a string of successes spanning almost a decade. With Steve’s new critically acclaimed book, published in November 2024, he ensures that these insights can be accessed by all. Inspiring Integrity: How to Win with Compliance and Propel Performance became a #1 Best Seller on Amazon in multiple business categories, and both Steve and his book have been featured in USA TODAY, Business Insider, Benzinga, and Yahoo Finance. A boutique firm with a strong culture and an impeccable track record, it is our pleasure to once again celebrate TRESTLE Compliance, LLC in this awards programme. We wish this life sciences compliance and risk assessments expert all the best for the future and invite any interested reader to follow the link below for more. Contact: Steve Vincze Company: TRESTLE Compliance, LLC Web Address: https://TRESTLEcompliance.com/ When Steve Vincze established TRESTLE Compliance in 2017, he did so in order to provide partner-level expertise they sought to truly hit their stride. As entrepreneurs themselves, Steve and the team recognize just how important agility and speed to market are when it comes to nurturing success in life sciences compliance. This is why an emphasis is placed on the creation of customized, scaled solutions, with delivery of these being swift, precise, and of an unmatched value. An expert in everything from sales and false claims to privacy and anti-corruption, Steve is leveraging the expertise he has nurtured over the years in such positions as a senior leader at Deloitte and an officer in the Marine Corps to lead TRESTLE Compliance effectively from the front. Beyond Steve’s unique insights, the company’s team of devoted individuals draw from experiences across the likes of US Congress, a number of the Big 4 consulting/law firms, and even creative and software-based roles. “At TRESTLE, you won’t have a junior-level consultant learning on your time and dime. Instead, you’ll get direct access to professionals who can quickly identify risk and implement resourceful and effective solutions.” TRESTLE Compliance is proud to be able to offer frameworks designed to support and drive impact for life sciences businesses at every phase of their development. So, whether they are rallying investors for the first round of funding with the assurance of effective compliance controls, or are imminently set to release a new product to the market, this company has the right support solution. Its comprehensive service suite is the perfect embodiment of this, spanning from board and C-suite compliance to compliance monitoring and auditing, risk assessments, and more. Just one example of a recent project carried out by the team was a HIPAA (Health Insurance Portability and Accountability Act) risk assessment and US privacy programme for an ex-US biotech company that operates internationally but keeps its commercial operations working out of the country. Enterprises such as this one need to make sure they have a privacy programme that can help them identify the risks associated with working in a sector defined by increasing virtual methods of communication. Not only does TRESTLE Compliance help businesses navigate this Those in search of a business partner to take their pharmaceutical, biotechnology, or MedTech business to the next level need look no further than TRESTLE Compliance, LLC, a company specialising in the creation and delivery of both precision compliance risk assessments and tailored compliance programes. Adding immediate, measurable value to the operations it partners with, this Boston-based company is one of more than 1,000 biotechnology businesses in the region building the future of this space. Best Life Science Commercial Business Compliance Specialists 2025 – North America & GHP Innovation Excellence Award 2025 TRESTLE Compliance, LLC
12 GHP Biotechnology & Lifesciences Awards 2025 Establishedin2002,Connect2Cleanrooms is a highly experienced cleanroom lifecycle solution company providing only the most effective modular cleanroom solutions for a myriad of manufacturing environments. We explore its flexible, professional, and direct approach to supplying a diverse range of environments with its exceptional products as it was recently named in our Biotechnology&LifesciencesAwards2025. Beginning its journey of creating modular cleanrooms for a spectrum of environments over two decades ago, Connect 2 Cleanrooms has a wealth of knowledge in this business critical arena. Many organisations require modular cleanroom solutions for manufacturing environments such as injection moulding, which, ultimately, require a clean, controlled, and adaptable environment for premium operations. Connect 2 Cleanrooms’ 23 years of experience has led it to working with a varied, and expanding, variety of industries including manufacturing, electronics, semiconductor, medical, healthcare, automotive, and aerospace. The company’s client base is rapidly growing as it is able to work with businesses of any and all sizes. Recognising the need for specialist modular cleanrooms sweeping across the corporate landscape, Connect 2 Cleanrooms produces controlled environments for small scale start-ups in need of cost-effective yet successful cleanrooms as well as large, industry experts in need of more complex, sophisticated designs and features within their environmental controls. Marketing Manager Max McLeod told us: “We were also the first cleanroom company to offer a full, life-cycle suite of services, meaning that we offer a cleanroom design and build service along with cleanroom validation, cleanroom furniture and consumables and cleanroom training, making us a one-stop-shop for any cleanroom project. Through Connect 2 Cleanrooms we provide our design and build, validation and training services while Cleanroomshop.com provides everything that goes inside your cleanroom from a consumable perspective, such as wipes, sprays, coveralls, gloves etc.” In addition, having recently developed a new range of Laminar Flow Cabinets which include innovative features based on previous feedback for its existing units, Connect 2 Cleanrooms released its pioneering design in February this year to address any pain points existing in the modular cleanroom industry. This new design is now officially available via Connect 2 Cleanrooms where any business can access the next generation of cleanrooms. The new Laminar Flow Cabinets’ features include a 3-speed fan control, enhanced LED lighting, and an improved sash to reduce the ingress of contaminated air within each working environment – truly delivering the future of Laminar Flow Cabinets in the present day. Always adapting and flexing its creative muscles, while staying true to the needs of its many clients, Connect 2 Cleanrooms continues to improve the sphere for a range of sectors in need of the most suitable cleanrooms from a dedicated trailblazer consistently responding to the shifts in the industry. Max enthused: “We are also working to develop some new ideas for our predesigned range of cleanrooms, watch this space to see what we come up with!” Although working tirelessly across a mixture of industries and sectors, including healthcare and life sciences companies striving to enhance the well-being of all of us, Connect 2 Cleanrooms has found itself responding to more and more technological advancements. This has meant that an increasing amount of businesses require a sophisticated cleanroom to carry out their daily operations. Max shared: “A great example of this is a cleanroom that we built for a Company called Xpanceo based in Dubai. They are developing smart contact lenses that display images directly onto the eye and require a controlled environment for conducting activities to do with the production of these sensitive devices. Companies all over the world are competing in a race to develop their technologies and be the first to make the next cutting-edge advancements.” The global economy is in a constant state of fluctuation – from overseas market turbulence to the challenges faced after Brexit in the UK – Connect 2 Cleanrooms’ tight-knit team do all they can to reduce the implications of not only the complications of the global corporate landscape but also the implications imposed to a British company operating across the map. Creating controlled environments which are certified to ISO or GMP standards, Connect 2 Cleanrooms’ team – from project managers to operations personnel and procurement specialists to fully trained and accredited validation engineers – guarantee that the company stays ahead of the curve and competition, all for the benefit of its clients. This deeply caring, collaborative, progressive, and award-winning one-stop-shop for cleanroom design and build, validation, training, consumables, and furniture is altering the modular cleanroom craft as we know it. Contact: Max McLeod Company: Connect 2 Cleanrooms Website: https://connect2cleanrooms.com/ Cleanroom Design & Installation Company of the Year 2025
13 GHP Biotechnology & Lifesciences Awards 2025 or over three decades, Altasciences has been dedicated to offering a proven, flexible approach to early-phase drug development to pharmaceutical, biotechnology, and biopharma companies throughout the industry. The company partners with sponsors to help support educated, faster, and more complete early drug development decisions, integrating full-service solutions to safely accelerate development timelines by up to 40%. Altasciences began in 1995 as a clinical research contract research organisation (CRO) and bioanalytical lab focused on generic drug development. However, the company identified a gap in the market. “We saw an opportunity to reimagine early-phase drug development by creating a fully integrated model in which every facet of the process would be united under one organisational roof,” explained Marie-Hélène. After conducting extensive market research that validated this need, Altasciences embarked on a transformative journey starting in 2010, strategically acquiring CROs from across different areas of early-phase drug development, along with a CDMO. Today, the company boasts nine facilities across Canada and the United States, as well as an office in the UK, supporting preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, and formulation and manufacturing. The operation of these services are centralised and supported by communicative teams and systems. Compared to its market peers, Altasciences delivers the only truly integrated, one-stop solution in the early-phase sector. This approach stands out in a competitive market because it removes the need for multiple service providers and centralises scheduling, finance, and overall communication for clients. Key research activities can occur in parallel, rather than sequentially, enabling swift and seamless transitions from one milestone to the next. “At Altasciences, we’ve built a model that safely removes bottlenecks and gatekeepers,” Marie-Hélène told us. “Our goal is simple: to ensure data flows seamlessly and efficiently without compromising quality. We don’t cut corners; we simply remove the inefficiencies to help sponsors get better drugs to the people who need them faster.” A leader in its field, Altasciences has experienced exponential growth over a short period of time, continually increasing its capacity and expanding its comprehensive service offering to consistently meet the industry’s ever-evolving and complex needs. In 2018, the company added its first preclinical safety The conventional development process is unnecessarily fragmented and lengthy. Typically, sponsors must partner with multiple specialist CROs, and in turn, a lot of coordination is needed, often leading to miscommunication and handoffs. But with Altasciences, all aspects of early-phase drug development come together under one roof to provide a more efficient and simplified drug development experience. We found out more from Marie-Hélène Raigneau, President at Altasciences, in the wake of the company’s deserved recognition in the Biotechnology and Lifesciences Awards 2025. Best Biopharmaceutical CRO 2025 testing facility in Seattle to its portfolio, before acquiring more facilities from 2020 to 2023: a manufacturing and formulation company in Philadelphia; a third clinical site in Los Angeles; and three more preclinical facilities in Columbia, Scranton, and Sacramento. In 2023, Altasciences established its first foothold in Europe with an office in the UK dedicated to supporting its European clients. During this period, the company also invested in significant enhancements and expansions to its facilities, completing an expansion to its bioanalytical laboratories in Laval in 2021 and Columbia in 2023. Alongside this, 2023 also saw the construction of a new 53,000-square-foot building at its facility in Philadelphia, complete with a client-dedicated space for Phase 1 through to commercial manufacturing. Driven by a relentless pursuit of excellence, Altasciences has cultivated a team built upon the foundation of respect, quality, integrity, client-centricity, and employee development. These core values empower each member of Altasciences to move in unison, working cross-disciplinarily and collaboratively on projects to tackle challenges and push innovation. This synergy enables Altasciences to maximise opportunities for success and proactively overcome project-specific hurdles, resulting in a seamless and efficient drug development experience for its clientele. “In 2025, Altasciences is celebrating 30 years as a trusted partner in drug development,” Marie-Hélène announced. “Our success stems for one key principle: listening—truly listening— to our clients’ needs today while anticipating what they’ll need tomorrow. Looking ahead, we remain committed to listening, and to exploring new capabilities and technologies that align with current industry needs and international regulations, while continuing to lead the way in novel approaches to early drug development.” Contact Details Contact: Julie-Ann Cabana, Chief Marketing Officer Company: Altasciences Web Address: www.altasciences.com F Feb25169
14 GHP Biotechnology & Lifesciences Awards 2025 ince its establishment in 2018, Mestastop has been dedicated to finding treatment for metastatic cancer, working tirelessly to help medical oncologists delay metastasis through the development of small molecules and diagnostics. Currently, approximately 90% of cancer patients die from metastatic illness, making it the leading cause of cancer-related death and linked to poor patient prognosis, yet the standard therapies do not prevent nor cure metastasis. Most patients experiencing advanced-stage or high-risk tumours still pass away from metastatic disease or treatment-related problems, even with the advanced development of new therapies in the last two decades. Data from recent publications suggest that most cancer medications approved by the FDA have had little to no impact on quality of life, progression-free survival, or overall survival. Mestastop believes that a significant increase in these areas is only possible when metastasis is prevented. When all other clinical trials towards targeted anti-metastatic agents have failed, Mestastop takes an alternative approach to its operations, employing reverse translational biology that starts from patient tumour-based data and connecting it with individual patients’ follow-up survival and metastasis data to understand the biology of metastasis and identify novel first-in-class targets. This bedside-to-bench approach is the differentiator of Mestastop’s platforms. Its platforms are based on clinical patient data and help identify the key rate-limiting steps in the metastasis process. “In contrast to the initial understanding that dissemination was mostly responsible for metastasis, Mestastop data suggests that the ability of disseminated cells to adapt in the secondary microenvironment plays an important role,” Arnab states. “Mestastop assumes that cells have already disseminated during the diagnosis of primary tumours and focuses on preventing these cells from adapting in AIS-Feb25012 S Metastatic cancer is responsible for approximately 90% of cancer deaths. Often referred to as stage 4 cancer, metastasis occurs when cancer cells spread from the primary site to other parts of the body, travelling through the bloodstream or lymphatic system to reach distant organs or tissues. Mestastop Solutions is a leading company focused on developing treatments for metastatic cancer, specialising in drug discovery and predictive diagnostics to address cancer metastasis as early as possible. Here, we speakwithArnabRoyChowdhury,Founder and Director of Mestastop Solutions, to learn more about the company’s exceptional endeavours. the secondary microenvironment. Based on this understanding, we have identified three novel first-in-class targets playing a critical role in the adaption biology.” To remain a leader in this dynamic field, Mestastop Solutions is meticulous in its operations, working closely with a Tumour Review Board and internal ethics committee when sourcing tumours for research. It obtains individual consent forms to ensure that each patient is informed and agrees to the use of their tumour samples for research purposes. What’s more, the company adheres to all protocols related to animal safety and wellbeing throughout its research and has all cell and molecular biology work approved by an internal biosafety committee, ensuring that its research practices consistently meet safety standards and regulations. Mestastop Solutions maintains such high standards of operations due to the exceptional team driving its research. The company comprises 16 professionals, six of whom possess PhDs, and is dedicated to curating a productive, innovative internal culture. When expanding the team, Mestastop Solutions seeks out individuals possessing scientific integrity, attention to detail, motivation, the ability to be a team player, and precise and clear communication skills. These qualities are essential for prosperity in the rapidly advancing landscape of oncology and guarantee sustained success for Mestastop Solutions as it continues to champion effective treatment for metastasis. “Science thrives in a non-hierarchical system, where everyone is treated equally and any ideas can be great, irrespective of the person or his seniority,” says Arnab. “Mestastop Solutions has built a team that rallies around themselves by imbibing a culture of celebrating each other’s success and fostering open innovation. Additionally, the team is self-critical and does not fall in love with their ideas; they are bold in their vision but are critical and ruthless in their interpretation. Mestastop Solutions lets science do the talking.” Moving forward, we learn that Mestastop has a year of innovation ahead. In 2025, the company plans to start the Investigational New Drug filing process with the FDA for its phase III repurposing clinical trial candidate. Additionally, it intends to hire a Chief Business Officer in the USA, who will bring more than three decades of experience in pharmaceutical drug discovery and deal-making to the team. This strategic move will bolster Mestastop’s clinical trial efforts and propel the company forward on its mission of developing successful treatment for metastatic cancer. Contact: Arnab Roy Chowdhury Company: Mestastop Solutions Pvt Ltd Web Address: https://mestastop.com/ Best Metastasis R&D Specialist 2025 & GHP Innovation Excellence Award 2025
ghpnews.digitalRkJQdWJsaXNoZXIy NTY1MjM3